<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093273</url>
  </required_header>
  <id_info>
    <org_study_id>OPV 0213</org_study_id>
    <nct_id>NCT02093273</nct_id>
  </id_info>
  <brief_title>Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)</brief_title>
  <official_title>Phase II, Randomized, Double Blind, Prospective Intervention Study to Evaluate the Immunogenicity and Safety Profile of tOPV (Bio Farma) With Different Batch Numbers in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <authority>Indonesia: National Agency of Drug and Food Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the antibody response 30 days after two doses of t
      OPV
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial design is phase II, randomized, double blind, prospective intervention study. The
      subject study are 240 healthy, full term, newborn infants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To compare the antibody response 30 days after two doses of tOPV</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>antibody titer to Polio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To asses and compare the safety of tOPV</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Data collection of local and systemic reaction after immunization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To describe the antibody response after two doses of tOPV</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of titer antibody</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>tOPV commercial batch (Bio Farma)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tOPV pilot batch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tOPV pilot batch</intervention_name>
    <description>the tOPV vaccine is given orally</description>
    <arm_group_label>tOPV pilot batch</arm_group_label>
    <other_name>tOPV (Bio Farma)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tOPV commercial batch</intervention_name>
    <description>tOPV vaccine is given orally</description>
    <arm_group_label>tOPV commercial batch (Bio Farma)</arm_group_label>
    <other_name>tOPV (Bio Farma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, full term, newborns infants

          -  newborn residing within a relatively short and easily accessible distance A(&lt;30km)
             from the study clinic(s) and not planning to travel away during the entire study
             period

          -  Infant born after 37 weeks of pregnancy

          -  Infant weighing 2.5kg or more at birth (birth weight &gt;= 2.5kg)

          -  Healthy newborns, with no history of asphyxia or meconium aspiration

          -  Father, mother or legally acceptable representative properly informed about the study
             and having signed the informed consent form.

          -  Parents will commit themselves to comply with the indications of the investigator and
             with the schedule of the trial

          -  Mother at least elementary school graduate

        Exclusion Criteria:

          -  Child concomitantly enrolled or scheduled to be enrolled in another trial

          -  Known history of congenital or acquired immunodeficiency (including HIV infection)

          -  Evolving moderate or severe illness, especially infectious diseases or fever
             (axillary temperature &gt;=37.5oC

          -  Newborns requiring hospitalization at birth

          -  Infant immunized with non-scheduled OPV or IPV during trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy Fadlyana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health of Medicine Padjadjaran University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garuda Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibrahim Adjie Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puter Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Padasuka Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tOPV</keyword>
  <keyword>Antibody response</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
